Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zevra Therapeutics

7.66
+0.34004.64%
Pre-market: 7.01-0.6500-8.49%06:04 EDT
Volume:577.20K
Turnover:4.35M
Market Cap:414.53M
PE:-3.36
High:7.68
Open:7.23
Low:7.19
Close:7.32
Loading ...

Strategic Advancements and Promising Outlook Drive Zevra Therapeutics’ Growth Prospects

TIPRANKS
·
13 Nov 2024

Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...

GuruFocus.com
·
13 Nov 2024

Zevra Therapeutics: Strong MIPLYFFA Launch and Strategic Investments Justify Buy Rating Despite OLPRUVA Challenges

TIPRANKS
·
13 Nov 2024

Zevra Therapeutics’ Transformative Third Quarter 2024

TIPRANKS
·
13 Nov 2024

Zevra Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
13 Nov 2024

Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates

Zacks
·
13 Nov 2024

Zevra Therapeutics: Q3 Earnings Snapshot

Associated Press Finance
·
13 Nov 2024

Zevra Therapeutics Q3 2024 GAAP EPS $(0.69) Misses $(0.42) Estimate, Sales $3.695M Miss $4.869M Estimate

Benzinga
·
13 Nov 2024

Zevra Therapeutics Inc -Qtrly Shr Loss $0.69

THOMSON REUTERS
·
13 Nov 2024

Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates

GlobeNewswire
·
13 Nov 2024

Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates

Zacks
·
12 Nov 2024

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

GlobeNewswire
·
12 Nov 2024

William Blair pharmaceuticals analysts hold analyst/industry conference call

TIPRANKS
·
12 Nov 2024

Zevra Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview

Reuters
·
09 Nov 2024

Buy Rating for Zevra Therapeutics Driven by High Valuation Potential of Priority Review Voucher

TIPRANKS
·
06 Nov 2024

BRIEF-Zevra Therapeutics To Report Third Quarter 2024 Financial Results

Reuters
·
31 Oct 2024

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

GlobeNewswire
·
31 Oct 2024

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks
·
30 Oct 2024

Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline

Zacks
·
29 Oct 2024

Zevra Therapeutics Inc (ZVRA) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ...

GuruFocus.com
·
10 Oct 2024